This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Today's Health Winners and Losers

Shares of Amedisys (AMED - Get Report) were among the worst-performing health-related stocks Thursday, tumbling 24% after the home-health nursing company posted fourth-quarter earnings that were well below forecasts and announced the resignation of its chief financial officer.

The company earned $7.3 million, or 45 cents a share, on service revenue of $118.9 million. Analysts surveyed by Thomson First Call expected earnings of 55 cents a share on revenue of $117.9 million. During the year-earlier period, the company earned $6.1 million, or 39 cents a share, on sales of $64.4 million. Amedisys blamed the weak fourth-quarter earnings on the "transitional cost and delayed timeline expectations for performance improvement from the recent acquisitions of Housecall and Spectracare, the as yet unrealized synergies from the reduction in Housecall's corporate office expenses and the residual impact of last summer's hurricanes."

For 2006, Amedisys continues to predict earnings of $2.33 to $2.43 a share, with sales of $510 million. Analysts project earnings of $2.42 a share on sales of $516 million.

Amedisys said CFO Gregory Browne resigned to pursue other opportunities. The company has hired a search firm to aid it in finding a successor. Browne, meanwhile, will continue to serve as CFO until a replacement is found and transitioned, the company said. Shares were trading down $9.80 to $30.80.

GTC Biotherapeutics (GTCB) shares plunged 39% after the biopharmaceutical company said an advisory committee of the European Medicines Agency plans to issue a negative opinion related to the company's application for ATryn, a recombinant form of human antithrombin. "On the basis of recent conversations, GTC understands that the CHMP, after excluding data from pregnant patients, determined that an insufficient number of surgical patients were enrolled to support approval," the company said in a statement. GTC said it plans to use the appeals process to ask the agency to re-examine the application. Shares were trading down 87 cents to $1.38. Nearly 21 million shares have changed hands, compared with an average daily volume of just 764,219 shares.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,416.85 +225.48 1.31%
S&P 500 2,021.34 +19.18 0.96%
NASDAQ 4,681.4820 +43.4880 0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs